Abstract 669P
Background
Selpercatinib, a first-in-class highly selective and potent rearranged during transfection (RET)-inhibitor, demonstrated efficacy in treatment of RET-driven cancers in the phase 1/2 LIBRETTO-001 trial. We report patient-reported outcomes for non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), non-MTC thyroid cancer (TC) (15 Jun 2021, data cut-off date) and tumor agnostic (TA) cohorts (24 Sep 2021, data cut-off date).
Methods
Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) at baseline (BL), approximately every 8 weeks until cycle 13, and then every 12 weeks until end of treatment (EoT). Subscales were scored 0–100; higher scores indicate better functioning or more severe symptoms based on the subscale. Proportion of patients with improved, stable, or worsened status post-BL was assessed. For symptom subscales improved is 10-point decrease from BL, worsened is 10-point increase from BL, and stable is being within 10 points from BL. For other subscales improved is 10-point increase from BL, worsened is 10-point decrease from BL, and stable is being within 10 points from BL.
Results
For patients with NSCLC, MTC, TC, and TA, respectively, 200 (63%), 208 (71%), 32 (70%), and 28 (68%) patients completed BL assessment; compliance rate was 85%, 87%, 72%, and 86%. BL functional domain subscale scores were >65 points across cohorts. Mean (SD) BL global health status (GHS) scores were: NSCLC – 62 (24), MTC – 65 (24), TC – 73 (20), and TA – 59 (26). The highest BL symptom scores (mean [SD]) were: NSCLC – fatigue (37 [26]) and dyspnea (30 [29]), MTC – diarrhea (42 [38]) and fatigue (36 [27]), TC – insomnia (28 [27]) and fatigue (27 [24]), and TA – fatigue (40 [29]) and appetite loss (37 [36]). Change in post-BL status varied across cohorts (Table).
Table: 669P
Proportion of patients with post-BL response (Cycle 3 to EoT), mean (SD) | ||
NSCLC | ||
GHS | Improved | 42 (9) |
Stable | 42 (10) | |
Worsened | 17 (8) | |
Fatigue | Improved | 44 (7) |
Stable | 27 (5) | |
Worsened | 29 (9) | |
Dyspnea | Improved | 34 (6) |
Stable | 57 (5) | |
Worsened | 9 (4) | |
MTC | ||
GHS | Improved | 37 (7) |
Stable | 45 (4) | |
Worsened | 19 (7) | |
Fatigue | Improved | 46 (6) |
Stable | 28 (5) | |
Worsened | 26 (8) | |
Diarrhea | Improved | 53 (5) |
Stable | 35 (3) | |
Worsened | 12 (4) | |
TC | ||
GHS | Improved | 21 (9) |
Stable | 54 (8) | |
Worsened | 25 (6) | |
Fatigue | Improved | 39 (10) |
Stable | 32 (14) | |
Worsened | 30 (11) | |
Insomnia | Improved | 24 (14) |
Stable | 56 (7) | |
Worsened | 21 (13) | |
TA | ||
GHS | Improved | 39 (10) |
Stable | 44 (8) | |
Worsened | 17 (4) | |
Fatigue | Improved | 49 (12) |
Stable | 19 (9) | |
Worsened | 33 (11) | |
Appetite loss | Improved | 44 (9) |
Stable | 51 (13) | |
Worsened | 5 (6) |
Conclusions
The majority of patients with RET-driven cancers remained stable or improved on most QLQ-C30 domains during treatment with selpercatinib.
Clinical trial identification
NCT03157128.
Editorial acknowledgement
Leo J. Philip Tharappel, an employee of Eli Lilly Services India Private Limited provided medical writing and editorial assistance.
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
H. Kang: Financial Interests, Institutional, Research Funding, clinical trial contract: Eli Lilly and Company, Exelixis; Financial Interests, Personal, Speaker, Consultant, Advisor, honorarium: AXIS Med. L.E. Raez: Financial Interests, Personal and Institutional, Research Funding: Loxo, Eli Lilly and Company, Genentech, Pfizer, Novartis, Syndax, Guardant, Nanth Health, Natera, BMS, Merck, Velos. M. Khanal, Y. Han, S. Szymczak, S. Barker, A.M. Gilligan: Financial Interests, Personal, Full or part-time Employment: Eli Lilly and Company; Financial Interests, Personal, Stocks/Shares: Eli Lilly and Company. K. Wang: Financial Interests, Personal, Full or part-time Employment: TigerMed Grp. All other authors have declared no conflicts of interest.
Resources from the same session
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17
689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Presenter: Omkar Marathe
Session: Poster session 17